Cargando…

Acute Liver Failure in a Pediatric Patient with Congenital Dysery-Thropoietic Anemia Type I Treated with Deferasirox

Congenital dyserythropoietic anemias (CDA) represent a heterogeneous group of disorders characterized by morphological abnormalities of erythroid precursor cells and various degrees of hemolysis. Iron overload is a result of continuous hemolysis and recurrent transfusions. It is treated with iron ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Galina, Pinsk, Vered, Golan-Tripto, Inbal, Ling, Eduard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591501/ https://www.ncbi.nlm.nih.gov/pubmed/26487935 http://dx.doi.org/10.4081/hr.2015.5987

Ejemplares similares

Non-tuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide
por: Goldbart, Aviv, et al.
Publicado: (2021)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Is corticophobia spreading among pediatricians?—Insights from a self-efficacy survey on the management of pediatric atopic dermatitis
por: Andre, Nicolas, et al.
Publicado: (2023)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Israeli pediatricians’ confidence level in diagnosing and treating children with skin disorders: a cross-sectional questionnaire pilot study
por: Andre, Nicolas, et al.
Publicado: (2023)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Deferasirox in a refractory anemia after other treatment options: case report and literature review
por: Manduzio, Palma
Publicado: (2015)

Vitamin D deficiency in children with acute bronchiolitis: a prospective cross-sectional case- control study
por: Golan-Tripto, Inbal, et al.
Publicado: (2021)

Effect of Paediatric Atopic Dermatitis on Parental Sleep Quality
por: FORER, Ester, et al.
Publicado: (2023)

Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the −1774delG polymorphism in the Abcc2 gene
por: Braga, Caroline C. B., et al.
Publicado: (2017)

Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox
por: Ghazanfari, Azam, et al.
Publicado: (2019)

Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature
por: Miyake, Zenshi, et al.
Publicado: (2020)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Elevated Neutrophil-to-Lymphocyte Ratio Is Associated with Severe Asthma Exacerbation in Children
por: Arwas, Noga, et al.
Publicado: (2023)

Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching Hospital
por: Thakor, Dhaval R, et al.
Publicado: (2017)

Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes
por: Stomper, Julia, et al.
Publicado: (2022)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2020)

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
por: Di Tucci, Anna Angela, et al.
Publicado: (2007)

Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy
por: Senol, Sefika Pinar, et al.
Publicado: (2016)

Ferritin level changes and erythroid improvement in a group of adult polytransfused patients treated with Deferasirox
por: PARVU, ANDRADA VIORICA, et al.
Publicado: (2018)

A homozygous missense variant of SUMF1 in the Bedouin population extends the clinical spectrum in ultrarare neonatal multiple sulfatase deficiency
por: Staretz‐Chacham, Orna, et al.
Publicado: (2020)

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
por: Taher, Ali T., et al.
Publicado: (2018)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013)

Deferasirox: appraisal of safety and efficacy in long-term therapy
por: Chaudhary, Preeti, et al.
Publicado: (2013)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
por: Piolatto, Andrea, et al.
Publicado: (2021)

Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models
por: Kwan, Ping, et al.
Publicado: (2022)

Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery
por: Faizi, Hafsa Shahid, et al.
Publicado: (2022)

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis
por: Fucile, Carmen, et al.
Publicado: (2018)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
por: Adramerina, Alkistis, et al.
Publicado: (2022)

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
por: Tartaglione, Immacolata, et al.
Publicado: (2020)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

The potential of deferasirox as a novel therapeutic modality in gastric cancer
por: Choi, Jung Hye, et al.
Publicado: (2016)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4r3jsefjjcjpcarn01449l6huv